Hubert N. Caron

This study compares ex vivo short-term, organoid, and PDX drug screening methods in neuroblastoma, finding ex vivo screens are faster and more consistent with in vivo results.

The paper introduces a PDX platform for pediatric cancers, providing in vivo drug testing models and molecular data to aid in therapy development.

This study integrates immunohistochemistry and single-cell RNA sequencing data to characterize the immune landscape of pediatric brain and solid tumors, revealing distinct immune microenvironment features across tumor types.